AI for Drug Discovery and Longevity, w/ Rejuve CEOs Kennedy Schaal and Jasmine Smith
AI applications in drug discovery and longevity research with startup CEOs.
Guests
Kennedy Schaal
CEO, Rejuve Bio
Kennedy Schaal was CEO of Rejuve Bio, a biotechnology company using computational methods and biology to pursue therapies associated with aging and longevity. Her work focused on drug discovery and on developing treatments for diseases that may be underserved by conventional pharmaceutical economics.
Jasmine Smith
CEO, Rejuve AI
Jasmine Smith was CEO of Rejuve AI, a company focused on longevity research and building more representative health and aging datasets. Her work connected data, artificial intelligence, and biotechnology, with an emphasis on broadening participation in research and supporting the development of interventions related to healthy human lifespan.
Watch on YouTube ▶About this conversation
The most important, wide-reaching, and profound use case for AI might just be drug discovery. Normally it takes YEARS for scientists to develop drugs; AI can slash the timeline.
Kennedy Schaal is the CEO of Rejuve Bio, a startup that’s harnessing AI for faster drug discovery. And Jasmine Smith is the CEO of Rejuve AI, its sister company, which is racing to build a data-set that’s more equitable and inclusive and reflective of all humanity, with an end game of extending our longevity.
Kennedy and Jasmine discuss the current problems with drug discovery, how AI can help, and how AI can be especially impactful for more “niche diseases” that wouldn’t normally provide enough profit for Pharma companies to invest in.
Conversation with Rejuve Bio CEO Kennedy Schaal at (3:00).
Conversation with Rejuve AI CEO Jasmine Smith at (40:30).
Rejuve Biotech:
https://www.rejuve.bio
Rejuve AI:
https://www.rejuve.ai